Lung cancer in developing countries: access to molecular testing

The era of personalized medicine has come to the treatment of non-small cell lung cancer, and now molecular testing is part of the daily clinical decision, at least for patients with adenocarcinoma. Nevertheless, access to those tests is still very limited in the developing world. Developing countries must adapt their health care system to address that and grant access of patients with lung cancer to those tests. Because of several differences among developing countries, strategies will certainly vary from country to country. Issues such as generation of local molecular epidemiology data, quality control, education of health care professionals, development of innovative local and regional strategies, interconnection between regulatory pathways for the approval of drugs, and companion molecular tests are required.